Model TCB003 - CD19 CAR-T

TCB003 is an allogeneic CAR-T product using engineered GDTs from healthy donors and specifically targets CD19, which is highly expressed on a number of B cell malignancies. These malignancies, such as acute lymphoblastic Leukaemia (ALL) or diffuse large B cell lymphoma (DLBCL) arise when B cells replicate uncontrollably within the bone marrow, before progressing to the blood and circulatory system. Using the safety check of the gamma delta TCR, we have produced an allogeneic CAR-T product with significantly improved therapeutic index.